Sars-cov-2 infection risk by vaccine doses and prior infections over 24 months: prohepic-19 longitudinal study

HIGHLIGHTS

• What: In this context, the main objective of the study is to assess the risk of SARS-CoV-2 infections (including first infections, reinfections, and BTIs) JMIR Public Health Surveill 2024 | vol. 10 | e56926 | p 8 (page number not for citation purposes) Strengths and Limitations This study has several notable strengths. The authors provide crucial evidence supporting the effectiveness of vaccination against SARS-CoV-2 in reducing the risk of infection over different periods, up to 24 months from the onset of the pandemic. Although the objective of this study was not to analyze transmissibility, it provides . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.